McFarland Clinic PC-Jefferson

The trials here

What the 27 trials at this site are about, from their registry records.

Conditions

• Lung cancer8 trials
• Childhood cancers5 trials
• Pancreatic cancer3 trials
• Mantle cell lymphoma2 trials
• Metastatic breast cancer2 trials
• Multiple myeloma2 trials
• Triple-negative breast cancer2 trials
• Acute myeloid leukaemia1 trial
• Cervical cancer1 trial
• Chronic myeloid leukaemia1 trial
• Kidney cancer1 trial
• Liver and biliary tract cancer1 trial
• and 4 more

Phase

• Phase 214 trials
• Phase 39 trials
• Phase 2/32 trials
• Phase 1/21 trial

Status

• Active, not recruiting16 trials
• Completed10 trials
• Terminated1 trial

Lead sponsor

• SWOG Cancer Research Network12 trials
• ECOG-ACRIN Cancer Research Group10 trials
• Alliance for Clinical Trials in Oncology2 trials
• Eastern Cooperative Oncology Group1 trial
• GOG Foundation1 trial
• and 1 more

Running trials

• Active, not recruiting

  Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT05096663· Phase 2/3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

  NCT04647916· Phase 2· SWOG Cancer Research Network· Source

• Active, not recruiting

  Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

  NCT04233866· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

  NCT04268550· Phase 2· SWOG Cancer Research Network· Source

• Active, not recruiting

  A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

  NCT04115631· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

  NCT03654768· Phase 2· SWOG Cancer Research Network· Source

• Active, not recruiting

  Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

  NCT03419234· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia

  NCT03253848· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  NCT02785952· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

  NCT02595424· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

  NCT02445391· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT01863550· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

  NCT01415752· Phase 2· Eastern Cooperative Oncology Group· Source

Closed trials

• Terminated

  Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

  NCT04527549· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Completed

  Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

  NCT04173507· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296· Phase 2· SWOG Cancer Research Network· Source

• Completed

  Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast Cancer

  NCT03633331· Phase 2· Alliance for Clinical Trials in Oncology· Source

• Completed

  S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

  NCT02438722· Phase 2/3· SWOG Cancer Research Network· Source

• Completed

  Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

  NCT01824875· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Completed

  S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

  NCT01668719· Phase 1/2· SWOG Cancer Research Network· Source

• Completed

  S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

  NCT01101451· Phase 3· GOG Foundation· Source